Patent

Papillomavirus vaccines

The University of Queensland and CSL Limited

US 7,476,389 B1GrantedGranted Jan 13, 2009Filed Jul 20, 1992

A method of providing papilloma virus like particles which may be used for diagnostic purposes or for incorporation in a vaccine for use in related to infections caused by papilloma virus. The method includes an initial step of constructing one or more recombinant DNA molecules which each encode papilloma virus L1 protein or a combination of papilloma virus L1 protein and papilloma virus L2 protein followed by a further step of transfecting a suitable host cell with one or more of the recombinant DNA molecules so that virus like particles (VLPs) are produced within the cell after expression of the L1 or the combination of L1 and L2 proteins. The VLPs are also claimed per se as well as vaccines incorporating the VLPs.

Claims
20
3 independent claims
Filing to grant
16.5 years
Pendency

1ClaimsFirst of 20

  1. 1

    A method of making a papillomavirus virus-like particle, which method comprises:

    • constructing a recombinant DNA molecule that contains a sequence encoding a papillomavirus L1 protein;
    • transfecting a host cell with the recombinant DNA molecule;
    • expressing papillomavirus L1 protein in the host cell;
    • and obtaining papillomavirus virus-like particles from the transfected host cell;
    • wherein the papillomavirus is not HPV 16.

2Description

Field of Invention

THIS INVENTION relates to papillomavirus and in particular antigens and vaccines that may be effective in treatment of infections caused by such viruses.

Showing a preview — retrieve the full document via the Exa API.

Powered by the Exa API

See something wrong or missing on this page?